THE DEEP DATA SOLUTION FOR NOVEL DISCOVERIES IN ONCOLOGY
A world in which individual therapeutic treatments exist for every cancer patient – that is Indivumed’s vision. Using unmatched scientific capabilities and high-quality data and tissues all the way through, we chart the molecular reality of solid cancers, exposing how oncological diseases truly function.
By combining proprietary multi-omics and clinical datasets with AI-assisted advanced
analytics, we drive biomarker discovery as well as novel target identification and validation for potential therapies.
DISCOVERIES BASED ON UNIQUE DATA AND SAMPLES
Through our global network of partner clinics, we collect high-quality clinical data and tissue samples that reflect the molecular reality of cancer at an unparalleled level. Key to this are globally implemented standard operating procedures (SOPs) ensuring all clinical framework conditions are precisely fulfilled.
By combining multi-omics and clinical data we can drive in-silico research and development in cancer treatment, such as:
- discovery of new therapeutic drug targets, and
- assessment of molecular signaling pathways or identification of biomarkers and gene signatures for stratification of cancer patients.
The uniqueness of our samples is a result of standard collection and processing. Cold ischemia times of ≤10 minutes and collection of tumor and adjacent normal tissue from the same patient make our data unique.
Alongside the tissue, around 320 different clinical data points are collected.
The high quality of our tissue samples allows us to use a full multi-omics approach (proteomics, phosphoproteomics, transcriptomics, genomics, and miRNA).
Using next-generation sequencing and mass spectrometry technologies, we extract the deepest possible molecular information from tissue samples.
The raw data is quality controlled and processed with state-of-the-art technology and infrastructure, making it ready for cloud-based AI analysis.
Increasing the reliability, quality, and reproducibility of the data, our database constitutes an unparalleled resource with which to speed up discovery and development.
The powerful discovery machine
Utilizing our unique datasets and our powerful discovery and validation platform nRavel®, we drive the discovery of new therapeutic drug targets, the assessment of molecular signaling pathways, and the identification of biomarkers and gene signatures for the stratification of cancer patients.
nRavel® Rx: Target Identification and Validation,
In-silico and In-vitro
Using nRavel’s unique analytical power combining multi-omics data and deep clinical data with matched patient derived tumor models throughout our in-silico and in-vitro discovery workflows, we identify and validate new therapeutic drug targets.
Through combining multi-omic expression signatures and prognostic data in selected cohorts, we identify targets that are further characterized and subsequently prioritized using nRavel®.
Once a therapeutic drug target candidate has been successfully validated in-silico, the next step is to validate them in-vitro on 2D and 3D cell models derived from the original cohort used for the in-silico analyses.
nRavel® Dx: Precision Clinical Trial Design
Benefit from our experience and resources.
Utilizing insights from the target discovery process and our clinical and multi-omics database, clinical trial design can be optimized for each investigative drug. Biomarkers based on these insights facilitate patient screening and stratification, and ultimately speed up the recruiting process.
We partner with biotech or pharmaceutical companies as well as academic institutions to enhance R&D activities and launch new discovery programs, providing expertise, capabilities, and insight knowledge throughout the whole development process.
If you want to discuss a collaboration or learn more about our biomarker and target discovery pipeline, please do not hesitate to get in touch. We look forward to hearing from you.